Aardvark Therapeutics (AARD) News Today

Aardvark Therapeutics, Inc. (NASDAQ: AARD) is under pressure as multiple investor-rights law firms publicized a securities-fraud class action and urged shareholders to seek lead-plaintiff status. The legal headlines add reputational, financial and clinical-development risk, helping explain why the stock has decreased.

• Negative Sentiment: A securities class action has been filed against Aardvark and certain officers and directors on behalf of investors who bought shares in or traceable to the company’s February 2025 IPO, or who purchased securities between February 13, 2025, and May 14, 2026. The litigation could expose the company to damages, legal costs and continued negative publicity. Pomerantz class action announcement
• Negative Sentiment: The allegations center on statements that Aardvark’s ARD-101 drug had a highly favorable safety profile, was “99% gut-restricted,” and could produce Phase 3 data in early 2026. The lawsuits claim that cardiac observations later paused the HERO trial and led the FDA to impose a full clinical hold, suggesting potential discrepancies between prior investor communications and subsequent clinical events. AARD shareholder alert
• Negative Sentiment: Several firms, including Hagens Berman, Faruqi & Faruqi, Rosen, Levi & Korsinsky, and Wolf Haldenstein, issued additional notices on September 2–3. Although these releases largely repeat the same allegations and do not represent separate rulings against Aardvark, their volume may increase investor concern and selling pressure. Hagens Berman investor notice
• Neutral Sentiment: The announced October 13, 2026 deadline concerns investors seeking appointment as lead plaintiff; it does not determine the merits of the allegations. The cases remain unresolved, and the claims have not been proven in court. Faruqi lead plaintiff deadline notice